SAVA

NASDAQ

Cassava Sciences Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings9

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

News · 26 weeks20-100%

2025-10-262026-04-19

Mix690d

SEC Filings4(67%)
Other2(33%)

Latest news

25 items

42dSEC
SEC Form 10-K filed by Cassava Sciences Inc.
10-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
42dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
44dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer)
44dPR
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective March 11, 2026 AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced the rebranding of the Company, with a name change to Filana Therapeutics, Inc. ("Filana Therapeutics", or the "Company"). The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC
63dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
63dPR
Cassava Announces Closure of U.S. Department of Justice Investigation
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025. As previously disclosed, the Company reached a settlement with the U.S. Securities an
100dPR
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam's favorable safety profile in these studies Exploratory post-hoc analyses offer informative insights AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced publication of the article Phase 3 randomized clinica
121dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
122dSEC
Amendment: SEC Form 8-K/A filed by Cassava Sciences Inc.
8-K/A - CASSAVA SCIENCES INC (0001069530) (Filer)
126dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Other Events
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
127dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
137dSEC
SEC Form EFFECT filed by Cassava Sciences Inc.
EFFECT - CASSAVA SCIENCES INC (0001069530) (Filer)
141dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Other Events
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
149dINSIDER
Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
150dINSIDER
President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
154dINSIDER
President & CEO Barry Richard bought $201,809 worth of shares (73,385 units at $2.75) (SEC Form 4)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
162dSEC
SEC Form S-3 filed by Cassava Sciences Inc.
S-3 - CASSAVA SCIENCES INC (0001069530) (Filer)
162dSEC
SEC Form 10-Q filed by Cassava Sciences Inc.
10-Q - CASSAVA SCIENCES INC (0001069530) (Filer)
162dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
162dPR
Cassava Reports Q3 2025 Financials Results and Provides Business Update
Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third quarter ende
181dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Other Events
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
183dINSIDER
SEC Form 4 filed by Director Bir Dawn Carter
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
183dINSIDER
SEC Form 3 filed by new insider Bir Dawn Carter
3 - CASSAVA SCIENCES INC (0001069530) (Issuer)
183dSEC
Cassava Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
183dPR
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA, "Cassava", the "Company")), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value creation for pre-commercial and commercial biotechnology and life science companies including Reata Pharmaceuticals, Inc. (acquired by Biogen Inc.), Geron Corporation,